Microbix Biosystems

Microbix returns to MEDICA with new infectious disease antigens

Long-standing Canadian biotechnology company returns to MEDICA after a 15-year absence.

TORONTO, Canada Oct. 5, 2010 -- Microbix Biosystems Inc. (MBX:TSX), a Canadian biotechnology company with world-wide markets and focused on large-scale virology, is returning to MEDICA with a broad range of new and proven infectious disease antigens. Microbix cultures and purifies the world’s largest range of infectious disease antigens sold to diagnostic test manufacturers.

“Microbix last exhibited as a company in 1994, although as individuals we have attended MEDICA every year since. Now, we see 2010 as a great time and opportunity to return to MEDICA and exhibit our innovations to the world as part of the Ontario pavilion. Our antigens are used by over 65 other MEDICA exhibitors, so we know we will be welcomed back,” says Kevin Koole, General Manager of the Microbix Virology Business unit.

Earlier this year, Microbix expanded its sales force in Europe by opening a local office in Paris, France. The Company also expanded its efforts in India, and established a distribution centre in China to ease the burden associated with overseas shipping. These new distribution channels, along with a continually expanding and improving product line make Microbix viral antigens the choice of nine of the world’s 10 largest diagnostic manufacturers.

Our antigens include:
• Hepatitis A virus
• Rubella virus
• Chlamydia
• Dengue virus
• Adenovirus
• Parainfluenza virus
• Rotavirus
• Cytomegalovirus
• Herpes Simplex 1&2
• Measles virus
• Influenza virus
• Varicella-Zoster virus
• Respiratory syncytial virus
• Epstein-Barr virus

Microbix will be exhibiting in Hall 3, Booth K51 as part of the Ontario, Canada pavilion and welcomes new visitors and old friends.


For further information please contact Kevin Koole kevin.koole@microbix.com +1-905-361-8910 x228

Microbix Biosystems Inc. specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.